Energy substrate metabolism in cardiac hypertrophy

被引:0
|
作者
Michael F. Allard
机构
[1] St. Paul’s Hospital,The James Hogg iCapture Centre for Cardiovascular and Pulmonary Research, Room 166
来源
关键词
Cardiac Hypertrophy; Fatty Acid Oxidation; Glucose Oxidation; Substrate Utilization; Trimetazidine;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiac hypertrophy is a response to long-term pathologic (eg, hypertension) or physiologic (eg, exercise) hemodynamic overload accompanied by changes in energy substrate utilization. The pattern of substrate utilization (or metabolic phenotype) differs dramatically between pathologic and physiologic cardiac hypertrophy with directionally opposite changes in oxidation of fatty acids and glucose and glycolysis. These findings indicate that the metabolic response to long-term alterations in hemodynamic workload is not stereotypical, but is influenced by the nature of the stimulus leading to cardiac hypertrophy. Although the changes in substrate utilization are adaptive, in the case of pathologic stimuli, the changes in metabolism interfere with functional resiliency of the heart to metabolic stress, as occurs during ischemia-reperfusion. The distinct metabolic phenotypes of hearts hypertrophied in response to pathologic or physiologic stimuli are due not only to alteration in expression of metabolic enzymes and proteins, but also to post-translational modulation of metabolic enzymes and proteins.
引用
收藏
页码:430 / 435
页数:5
相关论文
共 50 条
  • [31] Sex differences in physiological cardiac hypertrophy are associated with exercise-mediated changes in energy substrate availability
    Foryst-Ludwig, Anna
    Kreissl, Michael C.
    Sprang, Christiane
    Thalke, Beata
    Boehm, Christian
    Benz, Verena
    Guergen, Dennis
    Dragun, Duska
    Schubert, Carola
    Mai, Knut
    Stawowy, Philipp
    Spranger, Joachim
    Regitz-Zagrosek, Vera
    Unger, Thomas
    Kintscher, Ulrich
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2011, 301 (01): : H115 - H122
  • [32] In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy
    Williams, Matthew J.
    Halabi, Carmen M.
    Patel, Hiral M.
    Joseph, Zachary
    Mccommis, Kyle
    Weinheimer, Carla
    Kovacs, Attila
    Lima, Florence
    Finck, Brian
    Malluche, Hartmut
    Hruska, Keith A.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2024, 326 (05) : F751 - F767
  • [33] INCREASED GLYCOLYTIC METABOLISM IN CARDIAC HYPERTROPHY AND CONGESTIVE FAILURE
    BISHOP, SP
    ALTSCHULD, RA
    AMERICAN JOURNAL OF PHYSIOLOGY, 1970, 218 (01): : 153 - +
  • [35] Modulating cardiac hypertrophy by manipulating myocardial lipid metabolism?
    Frey, N
    Olson, EN
    CIRCULATION, 2002, 105 (10) : 1152 - 1154
  • [36] ABNORMAL POLYAMINE METABOLISM IN HYPERTENSIVE CARDIAC-HYPERTROPHY
    SHIMIZU, M
    MASUDA, I
    AIHARA, K
    NAKANO, T
    OGAWA, K
    MIZOKAMI, T
    IRIMAJIRI, O
    TANIGUCHI, I
    OZASA, H
    KAGEYAMA, S
    HAYASHI, S
    ISOGAI, Y
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1988, 52 (10): : 1209 - 1215
  • [37] Cardiac metabolism in hypertrophy and heart failure: implications for therapy
    Siddiqi, N.
    Singh, S.
    Beadle, R.
    Dawson, D.
    Frenneaux, M.
    HEART FAILURE REVIEWS, 2013, 18 (05) : 595 - 606
  • [38] ABNORMAL POLYAMINE METABOLISM IN HYPERTENSIVE CARDIAC-HYPERTROPHY
    SHIMIZU, M
    MASUDA, I
    UTSUNOMIYA, K
    AIHARA, K
    OZASA, H
    TANIGUCHI, I
    KAGEYAMA, S
    ISOGAI, Y
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1986, 50 (08): : 718 - 718
  • [39] Does the lipidic metabolism of myocardium modulate cardiac hypertrophy?
    Planavila, A
    Jové, M
    Cabrero, A
    Carrera, AV
    NEFROLOGIA, 2004, 24 : 29 - 33
  • [40] Cardiac metabolism in hypertrophy and heart failure: implications for therapy
    N. Siddiqi
    S. Singh
    R. Beadle
    D. Dawson
    M. Frenneaux
    Heart Failure Reviews, 2013, 18 : 595 - 606